Recombinant Plasmid miRNA Composition for Apolipoprotein B Silencing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing therapies fail to effectively regulate the expression of bioactive molecules like apolipoprotein B, leading to homeostatic imbalance and associated diseases.
Innovation Solution
Compositions comprising recombinant plasmids that upregulate the production of micro-interfering ribonucleic acid (miRNA) sequences, which are complementary to the target mRNA of apolipoprotein B, thereby degrading or inactivating the mRNA to reduce the production of the biomolecule.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing therapies are used to regulate bioactive molecule expression, then treatment is provided, but they fail to effectively regulate apolipoprotein B expression leading to homeostatic imbalance
Solution Approach 1:
The patent uses miRNA as an intermediary molecule to mediate between the administered composition and the target mRNA. The miRNA binds to complementary sequences in apolipoprotein B mRNA, facilitating targeted gene silencing without directly modifying the gene itself, thus achieving effective and adaptable regulation of bioactive molecule expression
Solution Approach 2:
The patent changes the molecular parameters by introducing exogenous miRNA sequences with specific complementarity to target mRNA. This alters the RNA interference pathway parameters in the cell, enabling precise control over gene expression levels of apolipoprotein B and other bioactive molecules, thereby achieving reliable therapeutic effects
2Reliability
If miRNA production is upregulated to decrease target biomolecule bioavailability, then gene expression is suppressed, but the complexity of the composition increases
Solution Approach 1:
The patent segments the therapeutic function into distinct modular components: a backbone sequence for miRNA processing and multiple insert sequences encoding different miRNA variants. This modular structure allows the complex composition to be systematically organized, facilitating both effective gene suppression and manageable complexity through structured modularity
3Ease of operation
If plasmid vectors are used to deliver miRNA sequences, then cellular uptake and expression are facilitated, but the risk of genomic integration and off-target effects increases
Solution Approach 1:
The patent applies local quality control by designing the plasmid vector with specific features: a defined backbone sequence for controlled miRNA processing, multiple targeted insert sequences for specific gene silencing, and absence of strong promoters that could cause genomic integration. This localized optimization of vector properties enables efficient cellular delivery while minimizing harmful off-target effects through precise structural design
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compositions increase the production of miRNA, leading to decreased bioavailability of apolipoprotein B, thereby ameliorating the homeostatic imbalance and potential diseases caused by its dysregulation.
Implementation Method 1
the sequences of miRNA may be complimentary to a sequence of target messenger RNA (mRNA) that encodes for the translation of a target biomolecule, and the miRNA can cause the bioavailability of the target mRNA to decrease because it is degraded and/or inactivated by the miRNA
Data Source
AI summary
The embodiments of the present disclosure relate to decreasing the bioavailability of one or more target biomolecules by providing a composition that comprises a recombinant plasmid (RP) and one or more sequences of micro-interfering ribonucleic acid (miRNA). When the RP interacts with a target cell, it causes the target cell to upregulate production of the miRNA, which then decreases the bioavailability of the target biomolecule. In some embodiments of the present disclosure, the target biomolecule is an apolipoprotein.